[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Malaria - Pipeline Insight, 2021

June 2021 | 60 pages | ID: ME70648E7DD6EN
DelveInsight

US$ 1,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

DelveInsight’s, “Malaria - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Malaria Understanding

Malaria: Overview

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2019, there were an estimated 229 million cases of malaria worldwide. Malaria is caused by Plasmodium parasites. The parasites are spread to people through the bites of infected female Anopheles mosquitoes, called 'malaria vectors.' There are 5 parasite species that cause malaria in humans, and 2 of these species – P. falciparum and P. vivax – pose the greatest threat.

Malaria is an acute febrile illness. In a non-immune individual, symptoms usually appear 10–15 days after the infective mosquito bite. The first symptoms – fever, headache, and chills – may be mild and difficult to recognize as malaria. If not treated within 24 hours, P. falciparum malaria can progress to severe illness, often leading to death.

Early diagnosis and treatment of malaria reduces disease and prevents deaths. Antimalarial medicines can also be used to prevent malaria. For travellers, malaria can be prevented through chemoprophylaxis, which suppresses the blood stage of malaria infections, thereby preventing malaria disease. The most common antimalarial drugs include: Chloroquine phosphate, Chloroquine is the preferred treatment for any parasite that is sensitive to the drug.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Malaria R&D. The therapies under development are focused on novel approaches for Malaria.
Malaria Emerging Drugs Chapters

This segment of the Malaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malaria Emerging Drugs
  • R21: GlaxoSmithKline
R21/Matrix M- the new vaccine candidate, is a modified version of RTS, S - another candidate against malaria by GlaxoSmithKline. This is designed with an aim to stop the malaria parasite- Plasmodium falciparum from entering the liver and preventing the subsequent deadly blood stages. The vaccine targets the liver stage protein of the parasite’s life cycle.

It is currently in Phase III stage of development for the treatment of Malaria and is being developed by GlaxoSmithKline.
  • KAF156: Novartis
KAF156 is the first compound to progress into clinical development from the novel imidazolopiperazine class of antimalarial molecules. A key strength of the drug is its potential to both treat and prevent malaria, including resistant strains. Phase IIa studies have demonstrated that KAF156 rapidly kills both P. vivax and P. falciparum malaria parasites.

It is currently in Phase II stage of development for the treatment of Malaria and is being developed by Novartis.

Further product details are provided in the report..

Malaria: Therapeutic Assessment

This segment of the report provides insights about the different Malaria drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Malaria
There are approx. 20+ key companies which are developing the Malaria. The companies which have their Malaria drug candidates in the most advanced stage, i.e. Phase III include, GlaxoSmithKline.
  • Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Malaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malaria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Malaria therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malaria drugs.

Malaria Report Insights
  • Malaria Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Malaria Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Malaria drugs?
  • How many Malaria drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Malaria?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malaria therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Malaria and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • GlaxoSmithKline
  • Sanaria
  • Tarsus Pharmaceuticals
  • Novartis
  • Nobelpharma
  • Curevac
  • Novavax
Key Products
  • R21
  • KAF156
  • PfSPZ Vaccine
  • TP-05
  • INE 963
  • GSK-3437949A
  • NPC-19
  • KAE609
  • R0.6C
Introduction
Executive Summary
Malaria: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Malaria– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Malaria companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Malaria Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
R21: GlaxoSmithKline
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
  Comparative Analysis
KAF156: Novartis
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
  Comparative Analysis
NPC-19: Nobelpharma
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
  Comparative Analysis
Research Programme: Malaria: Carna Biosciences
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report..

Inactive Products
  Comparative Analysis
Malaria Key Companies
Malaria Key Products
Malaria- Unmet Needs
Malaria- Market Drivers and Barriers
Malaria- Future Perspectives and Conclusion
Malaria Analyst Views
Malaria Key Companies
Appendix

LIST OF TABLES

Table 1 Total Products for Malaria
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


LIST OF FIGURES

Figure 1 Total Products for Malaria
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


More Publications